Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 1046-1058
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1046
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1046
Table 2 Direct comparison of disease-free survival of various interventions
| Intervention 1 | Intervention 2 | Study number | I2 | P value | HR/95%CI |
| Neoadjuvant plus adjuvant FLOT | Neoadjuvant plus adjuvant ECF | 2 | 0 | 1.00 | 0.75 (0.65, 0.86) |
| Neoadjuvant plus adjuvant CF | Surgery alone | 1 | - | - | 0.69 (0.50, 0.95) |
| Neoadjuvant plus adjuvant XELOX | Surgery alone | 1 | - | - | 0.96 (0.25, 3.66) |
| Neoadjuvant plus Adjuvant SOX | Adjuvant SOX | 1 | - | - | 1.28 (0.33, 4.93) |
| Neoadjuvant plus adjuvant SOX | Adjuvant XELOX | 1 | - | - | 0.77 (0.61, 0.97) |
- Citation: Kuang ZY, Sun QH, Cao LC, Ma XY, Wang JX, Liu KX, Li J. Efficacy and safety of perioperative therapy for locally resectable gastric cancer: A network meta-analysis of randomized clinical trials. World J Gastrointest Oncol 2024; 16(3): 1046-1058
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/1046.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.1046